The TGA Repurposing Program is offering a special chance to explore new uses for existing medications. This could mean big benefits for people with conditions that don't have enough treatment options. Repurposing is all about finding different ways to use medicines that are already approved for other things.

The Australian POTS Foundation is putting forward Midodrine for repurposing through the TGA program. Midodrine is currently only ‘indicated’ for another autonomic condition called ‘orthostatic hypotension’, but it is also known to help with POTS.

Here's the thing: Medicines like Midodrine don't usually get the financial support needed to get registered on the TGA or the Pharmaceutical Benefit's Scheme (PBS). That's because there aren't many people who need them, so it is not profitable for drug companies to pay the expensive nomination fee required by the TGA.

However, the TGA Repurposing Program gives hope. It offers a chance for medications like Midodrine to be assessed for new uses and maybe even become part of the PBS. This could mean more people with POTS getting access to treatments that would otherwise be unaffordable.

If you or someone you know benefits from Midodrine, consider supporting its nomination. Every voice counts! And remember, reaching out to your local Members of Parliament (MPs) to support this nomination can make a big difference.

For more information and to get involved, check out the instruction page below. Let's work together to ensure that people with POTS get the help they need.

Follow the link below for instructions on how to nominate Midodrine as a member of the Public. Submissions close 17th April 2024